{"data":{"id":"sw_b23526d7e1324cac0a3f","slug":"amgen-nears-52-week-high-while-extending-dividend-growth-streak-past-14-years","title":"Amgen Nears 52-Week High While Extending Dividend Growth Streak Past 14 Years","subheadline":"The drugmaker's steady payout increases stand out against a market session dominated by high-beta tech names and a dividend cut at Wendy's.","summary":"Amgen trades near its 52-week high with a 14-plus year streak of dividend increases, offering a contrasting income profile as other yield names face cuts and markets chase risk assets.","body":"Amgen Inc. shares closed at $444.12 on September 3, 2026, up $1.28, or 0.29%, and sitting just below the stock's 52-week high of $447.03: a level reached within a range that also includes a low of $269.77 over the past year. The pattern first stood out in payment data tracked on Income Investing, a Madison Labs research site, which shows the biotechnology company's dividend has risen every complete calendar year for at least 14 consecutive years, based on stored records beginning in 2011.\n\nThat combination, a stock trading near a 52-week peak alongside an extended run of dividend increases, describes a company whose share price and cash distribution have moved in the same direction for an extended period. Amgen's most recent declared payment was $2.52 per share, with an ex-dividend date of August 21, 2026, and a pay date of September 11, 2026. Measured against the comparable payment from roughly a year earlier, that represents a 5.88% increase, according to the payment history. On a forward basis, annualizing the latest quarterly payment produces $10.08 per share; the trailing 12-month figure, reflecting cash actually paid out over the past year, totals $9.94 per share. Dividing either figure by the current share price puts Amgen's yield in the neighborhood of 2.2% to 2.3%, depending on whether the forward estimate or the trailing total is used: a reminder that the two measures are not interchangeable, since one is an estimate of future payments and the other reflects cash already received.\n\nFor income-focused investors, the notable element isn't the yield itself, which sits below levels typically associated with higher-payout sectors such as utilities or real estate investment trusts, but the consistency of the growth. A payout that increases annually, funded from a large-cap pharmaceutical company's earnings and cash flow, is a different proposition than a high headline yield that depends on the payment holding steady or a stock price staying depressed. Amgen's dividend is paid quarterly, and the company's own published record may extend the streak further back than the 2011 starting point captured in the available data, since the count is described as a floor rather than a definitive total.\n\nThe contrast matters because dividend cuts have been visible elsewhere in the market this year. Wendy's Co. cut its dividend in half, a move that market commentary has framed as a caution signal for income investors who may have assumed a payout was secure based on yield alone rather than on underlying earnings coverage. Amgen's payout ratio, the share of trailing earnings distributed as dividends, is a separate metric investors can weigh against the company's growth record, though any single ratio doesn't capture the full picture of a company's ability to sustain or grow a payment over time.\n\nBackground on Amgen's dividend history shows the company has built its increases on a business built around biologic drugs and, more recently, a broader manufacturing and research pipeline in the Drug Manufacturers - General industry classification. The stock trades on the Nasdaq under the ticker AMGN, and its common shares carry the standard characteristics of equity income: a board-declared payment with no obligation to continue, no par value floor, and no arrears if a payment were ever skipped.\n\nThe broader market backdrop on the day Amgen's price was last recorded showed a decidedly different tone in parts of the market. Shares of Palantir Technologies rose 7.7%, ServiceNow gained 6.5%, Oracle added 5.7%, and Tesla climbed 5.4%, according to trading levels tracked that day, while Bitcoin advanced 4.6% and Ethereum rose 5.7% in 24-hour trading. That mix of high-beta technology and cryptocurrency gains illustrates a session where risk appetite was elevated elsewhere in markets, a backdrop against which a steady dividend-growth name like Amgen represents a comparatively different risk and return profile, without any implication that one approach is preferable to the other.\n\nInvestors watching Amgen's dividend going forward are likely to focus on whether the company's board continues its pattern of annual increases when it next declares a payment, and on how the payout ratio evolves relative to earnings. The ex-dividend and pay dates for the next distribution, along with any change in the quarterly amount, will provide the next concrete data points in a streak that, on the record currently available, has not been broken since at least 2011. As with any equity dividend, the payment is not guaranteed and remains subject to the discretion of Amgen's board in future periods.","source":{"name":"Income Investing","slug":"incomeinvesting-ai"},"category":"Dividends","article_type":"News","license":"Free to republish, in full or in part, with attribution to SourceWire and a link to the original article. No fees, registration, or permission required.","quality_score":84,"human_reviewed":false,"original_url":"https://incomeinvesting.ai/stock/AMGN","featured_image":null,"published_at":"2026-09-04T11:27:28.242609+00:00","updated_at":"2026-09-04T11:27:28.242609+00:00","is_demo":false,"attribution":"Via SourceWire. Discovered via Income Investing.","attribution_html":"Via SourceWire. Discovered via Income Investing."},"meta":{"demo_data":false}}